Search information pages
About Infectious Agents and Cancer
This page includes information about the aims and scope of Infectious Agents and Cancer, editorial policies, open access and article-processing charges, the peer review process and other information. For details of how to prepare and submit a manuscript through the online submission system, please see the instructions for authors.
Aims & scope
Infectious Agents and Cancer is an open access, peer-reviewed online journal that encompasses all aspects of basic, clinical, epidemiological and translational research providing an insight into the association between chronic infections and cancer.
The journal welcomes submissions in the pathogen-related cancer areas and other related topics, in particular:
• HPV and anogenital cancers, as well as head and neck cancers;
• EBV and Burkitt lymphoma;
• HCV/HBV and hepatocellular carcinoma as well as lymphoproliferative diseases;
• HHV8 and Kaposi sarcoma;
• HTLV and leukemia;
• Cancers in Low- and Middle-income countries.
The link between infection and cancer has become well established over the past 50 years, and infection-associated cancer contribute up to 16% of cancers in developed countries and 33% in less developed countries.
Preventive vaccines have been developed for only two cancer-causing viruses, highlighting both the opportunity to prevent infection-associated cancers by vaccination and the gaps that remain before vaccines can be developed for other cancer-causing agents. These gaps are due to incomplete understanding of the basic biology, natural history, epidemiology of many of the pathogens that cause cancer, the mechanisms they exploit to cause cancer, and how to interrupt progression to cancer in human populations. Early diagnosis or identification of lesions at high risk of progression represent the current most critical research area of the field supported by recent advances in genomics and proteomics technologies.
Moreover “omics” is contributing to and accelerating the discovery not only of novel pathogens, but of genetic predisposition as the genetic make-up of organisms and individuals is unraveled. The hunt for molecular signatures of cancer causation, early cancer, or cancer Achilles heels promises new ways to practice precision medicine and public health. The explosion of knowledge in tumor genomics, tumor biology, targeted therapies, gene-environment interactions, immunology and immunotherapy needs a space for robust and vigorous debate.
Infectious Agents and Cancer will cover all these areas of biomedical research and any other topics pertinent to the development of preventive strategies, innovative diagnostic and biomolecular methodologies, promising therapeutic strategies for chronic infections and cancer. Immunotherapeutic strategies will include: profiling and activation of dendritic cells; reactivation of the immune system; breaking immune tolerance; modulation of the immune system by cytokines and drug delivery systems.
All articles published by Infectious Agents and Cancer are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
Authors of articles published in Infectious Agents and Cancer are the copyright holders of their articles and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate the article, according to the BioMed Central copyright and license agreement.
For authors who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Infectious Agents and Cancer therefore levies an article-processing charge of £1240/$1940/€1580 for each article accepted for publication. If the submitting author's institution is a Member, the cost of the article-processing charge is covered by the membership, and no further charge is payable. In the case of authors whose institutions are Supporter Members, however, a discounted article-processing charge is payable by the author. We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
All articles published in Infectious Agents and Cancer are included in PubMed, the most widely used biomedical bibliographic database service, which is run by the US National Library of Medicine. Other bibliographic databases that index articles published in Infectious Agents and Cancer include:
- Biological Abstracts
- Global Health
- Google Scholar
- Index Copernicus
- Journal Citation Reports/Science Edition
- PubMed Central
- Science Citation Index Expanded
The full text of all research articles is deposited in PubMed Central, the US National Library of Medicine's full-text repository of life science literature, and other digital archives including e-Depot (The Netherlands).
The full text of all research articles published by BioMed Central is also available on SpringerLink.
Infectious Agents and Cancer is tracked by Thomson Reuters (ISI) and has an Impact Factor of 2.07.
Publication and peer review process
Criteria for publication
Infectious Agents and Cancer considers the following types of articles:
Research articles: reports of data from original research.
Reviews: comprehensive, authoritative, descriptions of any subject within the journal's scope. Reviews can cover any topical themes such as basic science and clinical reviews, ethics, pro/con debates, equipment reviews and thematic series to highlight specific topics in the field. Reviews have an educational aim and are 2000-3000 words long.
Commentaries: short, focused and opinionated articles on any subject within the journal's scope. These articles are usually related to a contemporary issue, such as recent research findings, and are about 800 words.
Hypotheses: short articles presenting an untested original hypothesis backed solely by previously published results rather than any new evidence. They should outline significant progress in thinking that would also be testable, and be about 1500 words.
Letters to the Editor: they can take three forms: a substantial re-analysis of a previously published article, or a substantial response to such a re-analysis from the authors of the original publication, or an article that may not cover 'standard research' but that may be relevant to readers.
Meeting reports: a short description of a conference that the author has attended. It is usually best for the article to be published as soon after the meeting as possible, and should focus on the key developments presented and discussed at the meeting. These articles are usually commissioned but reports and suggestions may also be submitted for the editors' consideration.
Methodology articles: present a new experimental method, test or procedure. The method described may either be completely new, or may offer a better version of an existing method. The article must describe a demonstrable advance on what is currently available. The method needs to have been well tested and ideally, but not necessarily, used in a way that proves its value.
Short reports: brief reports of data from original research, usually about 1500 words.
Peer review policy
Manuscripts submitted to Infectious Agents and Cancer will undergo a preliminary evaluation by an Editor-in-Chief, who may reject it or assign it to the Managing Editor for review. The Managing Editor will then send the manuscript to at least two Editorial Board members or ad hoc external reviewers. It is expected that the review period will not exceed three weeks. Based on the reviews, the Editors-in-Chief will make the final decision to accept, accept following revisions, or reject the manuscript. Rejected works are permitted one additional round of re-submission. If the resubmitted work is declined again the decision is final.
Edited by Franco M. Buonaguro, George K. Lewis and Pier Giuseppe Pelicci, Infectious Agents and Cancer is supported by an expert Editorial Board.
Authors will be able to check the progress of their manuscript through the submission system at any time by logging into My Infectious Agents and Cancer, a personalized section of the site.
High-quality, bound reprints can be purchased for all articles published. Please see our reprints website for further information about ordering reprints.
Infectious Agents and Cancer will consider supplements based on proceedings (full articles or meeting abstracts), reviews or research. All articles submitted for publication in supplements are subject to peer review. Published supplements are fully searchable and freely accessible online and can also be produced in print. All full length articles (proceedings, reviews or research articles) are indexed by PubMed. PubMed displays the title of the supplement only in the case of meeting abstract collections. For further information, please contact us.
All manuscripts submitted to Infectious Agents and Cancer should adhere to BioMed Central's editorial policies.
Citing articles in Infectious Agents and Cancer
Articles in Infectious Agents and Cancer should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Infect Agents Cancer [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Infect Agents Cancer 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Why publish your article in Infectious Agents and Cancer?
Infectious Agents and Cancer's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience. Articles that have been especially highly accessed are highlighted with a 'Highly accessed' graphic, which appears on the journal's contents pages and search results.
Speed of publication
Infectious Agents and Cancer offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF; the article will then be available through Infectious Agents and Cancer, BioMed Central and PubMed Central and will also be included in PubMed.
Online publication in Infectious Agents and Cancer gives authors the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Infectious Agents and Cancer are included in article alerts and regular email updates. Some may be included in abstract books mailed to academics and are highlighted on Infectious Agents and Cancer's pages and on the BioMed Central homepage.
In addition, articles published in Infectious Agents and Cancer may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Infectious Agents and Cancer. A list of articles recently press-released by journals published by BioMed Central is available here.
Authors of articles published in Infectious Agents and Cancer retain the copyright of their articles and are free to reproduce and disseminate their work (for further details, see the BioMed Central copyright policy and license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.